Navigation Links
Einstein-Montefiore researcher will test nanoparticles against pancreatic cancer
Date:1/3/2011

January 3, 2011 ─ (BRONX, NY) ─ A five-year, $16-million grant from the National Cancer Institute will take advantage of specialized expertise developed by scientists at Albert Einstein College of Medicine of Yeshiva University and Montefiore, the University Hospital and Academic Medical Center for Einstein. The research carried out by a group of five institutions, including Einstein, that comprise the Texas Center for Cancer Nanomedicine could lead to novel ways to diagnose and treat pancreatic and ovarian cancer using nanoparticles.

Nanoparticles are engineered materials that are 100 nanometers or less in size. (A nanometer is one billionth of a meter.) Nanoparticles impregnated with drugs are called nanomedicines.

"We will be investigating nanomedicines for both imaging and treating pancreatic tumors," said Einstein-Montefiore principal investigator Steven Libutti, M.D., professor and vice chair of surgery at Einstein and Montefiore, director of the Montefiore-Einstein Center for Cancer Care, and associate director for clinical services of the Albert Einstein Cancer Center. "Our part of the consortium is developing nanoparticles that will specifically target unique aspects of the blood vessels found in pancreatic adenocarcinomas and pancreatic neuroendocrine tumors."

Pancreatic cancer is the fourth-leading cause of all cancer deaths. Currently, there is no test for early detection of the disease, which killed nearly 37,000 people in 2010. Only 5.6 percent of people diagnosed with pancreatic cancer live for five years or longer, according to the National Cancer Institute.

Dr. Libutti has developed mice that are genetically programmed to form pancreatic tumors that mimic those seen in people. These mice will be used for testing a variety of nanoparticle-based drugs produced by other collaborators. Such studies will reveal whether the particles can home in on disease locations and deliver therapeutic benefits. Dr. Libutti's clinical practice involves the surgical management of patients with cancer, including those with pancreatic cancer. A main focus of his research is the formation of new blood vessels that nourish tumors.

Identifying the most promising nanoparticle-based drugs for pancreatic as well as ovarian cancer will take several years. Clinical trials are not likely to begin until the end of the five-year project.


'/>"/>

Contact: Kim Newman
sciencenews@einstein.yu.edu
718-430-3101
Albert Einstein College of Medicine
Source:Eurekalert

Related medicine news :

1. Researchers map all the fragile sites of the yeast Saccharomyces cerevisiaes genome
2. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
3. Researchers discover new way to kill pediatric brain tumors
4. Researchers Who Discovered First Genes for Stuttering will Present Findings to the National Stuttering Association
5. Tiny fruit fly could offer big clues in fight against obesity, researcher says
6. Researchers create drug to keep tumor growth switched off
7. MSU researcher linking breast cancer patients with alternative therapies
8. UT researcher receives $2.4 million to research obesity, high-risk pregnancy
9. Urine protein test might help diagnose kidney damage from lupus, UT Southwestern researchers find
10. GUMC researchers say flower power may reduce resistance to breast cancer drug tamoxifen
11. Clemson researchers develop hands-free texting application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... The PAINWeekEnd ... Beach Resort and Spa in Honolulu, offering local frontline clinicians the opportunity to ... , The demand for supplemental training related to pain management has surged ...
(Date:12/2/2016)... ... ... Yisrayl Hawkins, at The House of Yahweh in Abilene, Texas, has published ... Yisrayl says this generation, known as the Last Generation, started in 1934 A.Y. (After ... up exactly with Bible Prophecy – a protected way for those who will believe. ...
(Date:12/2/2016)... ... December 02, 2016 , ... Today CloudMine, a ... applications, was named the best Sales Team of 2016 as part of the ... today by the Software & Information Industry Association (SIIA), the principal trade association ...
(Date:11/30/2016)... (PRWEB) , ... November 30, 2016 , ... ... that they now offer a comprehensive in-house dental plan for all patients. Understanding ... developed a plan that gives patients a number of perks, including discounts on ...
(Date:11/30/2016)... ... November 30, 2016 , ... Center ... has announced the opening of a new residential mental health treatment program in ... health issues such as severe anxiety, depression, bi-polar disorder, and other related issues. ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... - bioLytical lanza el INSTI HIV Self Test ... Continue Reading ... New: ... , , bioLytical Laboratories (la "Compañía"), ... está expandiendo el lanzamiento de su INSTI HIV Self Test  a África con ...
(Date:12/2/2016)... North America held the largest share in the ... aged population and demand for remote monitoring ECG devices. On ... region is expected to witness the highest growth rate during ... Company (U.S.), Becton, Dickinson and Company (U.S.), Medtronic plc ( ... Netherlands ) and Mindray Medical International Limited ( ...
(Date:12/2/2016)... Research and Markets has announced the addition of the ... 2022" report to their offering. ... , The global ultrasound device ... expected to grow at a CAGR of 5.5% during 2016-2022. Based on ... the forecast period, a CAGR of 8.8% in the global market. Among ...
Breaking Medicine Technology: